Additional file 1 of The effectiveness of adjunctive measures in managing peri-implant mucositis: an umbrella review

Additional file 1: Table S1. Eligibility criteria form. Table S2. Excluded reviews at the assessment of full-text and the main reasons for exclusion. Table S3. Characteristic of primary studies and overlap amongst systematic reviews of adjunctive antiseptic treatment. Table S4. Characteristic of primary studies and overlap amongst systematic reviews of adjunctive probiotic treatment. Table S5. Characteristic of primary studies and overlap amongst systematic reviews of adjunctive air-polishing treatment. Table S6. Characteristic of primary studies and overlap amongst systematic reviews of adjunctive laser and photodynamic treatment. Table S7. Characteristic of primary studies and overlap amongst systematic reviews of adjunctive local and systemic antibiotic treatment. Additional document 1. Data items of the systematic reviews and primary studies

Number of individuals among test (periodontitis) and control (healthy) groups according to HSP60 levels being undetectable, less or greater than 1000 ng/ml.

<p>Asterisk refers to statistically significant differences (P<0.05) between groups within each category as computed with Chi-square test.</p

Mean values (standard errors) and mean changes (standard errors) (compared to baseline) of HSP10 (A–B), BiP (C–D) and HSP60 (E–F) before, 24 hrs after and 6 months after periodontal therapy.

<p>Positive differences indicate a relative increase in plasma concentrations of various markers compared to the pre-treatment baseline. Subjects who received intensive periodontal therapy (open circles, N = 40) showed greater plasma concentrations of HSP10 at each time visit when compared to control therapy group subjects (filled circles, N = 40). No other changes were observed. Asterisks refer to statistically significant difference (P<0.05) between groups as computed with analysis of covariance.</p

Differences in plasma concentrations between patients suffering from periodontitis (N = 80) and age-matched unaffected controls (N = 48).

<p>Boxes refer to the 25^th (bottom) and 75^th (up) percentiles and the median is the large horizontal line, fences refer to the 10^th (lower) and 90^th (upper) percentiles respectively. Open circles represent outliers whereas asterisks stand for extreme observations with the subject number. Statistical differences are computed with Mann-Whitney U-test.</p

Case control study

*<p>Differences were computed with parametric (Independent t-test) or non parametric (Mann-Whitney U-Test) dependent upon the data frequency distribution. Categorical variables were analyzed by Chi-square testing.</p>**<p>See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001198#pone-0001198-g002" target="_blank">Figure 2</a>.</p

"Claude Tresmontant, la philosophie chrétienne et les présupposés d'une métaphysique de la Charité" [Claude Tresmontant, Christian Philosophy, and the Assumptions Behind a Metaphysics of Charity]

<p>A) Gingival health group; B) Gingivitis; C) Chronic periodontitis (original magnification ×40) (Bar 100 µm).</p

COX-2 gingival expression (median and inter-quartile range) and IL-6 cells positive in the periodontal connective tissue (CT) and outside CT in subjects divided by COX-2 rs 6681231 genotypes.

<p>*P = 0.032 Mann-Whitney U test.</p

Medians and inter-quartile range of clinical (Arbes index) and histological results for subjects divided by clinical diagnosis.

<p>a: Chi square test;</p><p>b: Kruskal-Wallis test.</p

Panoramic microphotograph of gingival biopsies.

<p>A) Gingival health group; B) Gingivitis; C) Chronic periodontitis. (Hematoxylin-eosin, original magnification ×2). (Bar 1000 µm).</p

Comparison between groups of studied periodontal, immunohistochemistry and genetic variables (n = 41).

<p>Continuous values are expressed as mean ± standard deviation;</p><p>a: Chi square test;</p><p>b: Kruskal-Wallis test;</p><p>c: Mann-Whitney U-test. Please note: Genotype results are available in 30/41 subjects for IL6 genotypes and in 34/41 subjects for COX-2 genotype.</p